Remove 2028 Remove Drug Development Remove Marketing
article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Drive: Drug Pricing

The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. But Jakafi’s main patents expire in 2028, a date that for years now has been on investors’ radar as they’ve pressed Incyte on what it expects will take the drug’s place.

Licensing 117
article thumbnail

Inside The Altascientist Issue 33: CNS Drug Development – Integrated Solutions Lessen Complexity

Alta Sciences

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD by 2028. billion USD in 2023 to $166.53 Image thumbnail-qh33.jpg

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Perficient Mentioned in Two Forrester Reports on Tech-Enabled Clinician Experiences

Perficient: Drug Development

And that’s easy to understand due to the plethora of available options and new solutions entering the market each day. According to Forrester, “Investment in hospital equipment will grow from $36 billion in 2018 to $262 billion in 2028. For many HCPs, a significant challenge we often see is technology overwhelm.

Nurses 98
article thumbnail

Disrupting the CRO Model: Altasciences Participates in Documentary Series for 2024 Global Health Summit

Alta Sciences

The mini documentary explores transformation in the slow-to-change drug development industry. Leaders from Altasciences dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and drug sponsors, and how Altasciences has broken from tradition to address these challenges.

article thumbnail

Nine Key Takeaways from Dreamforce 2023

Perficient: Drug Development

jobs by 2028. Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

This means that the medical device frameworks – including the pre-market pathways and evidentiary requirements, as well as post-market quality system frameworks and reporting requirements – are applied to the vast majority of all (CDRH-regulated) IVD products. IVDs used in blood donation screening/processing). In the E.U.,

FDA 40
article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. The study is planned to begin in 2026 and conclude in 2028.

FDA 40